Impairment of learning and memory and the accessory symptom in aged rat as senile dementia model (3)

Oral administration of propentofylline produces recovery of reduced NGF content in the brain of aged rats

Toshitaka Nabeshima, A. Nitta, T. Hasegawa

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The relationship between nerve growth factor (NGF) and senile dementia of the Alzheimer type is of interest. The administration of NGF in clinical trials has been expected; however, NGF cannot cross the blood brain barrier, since it is a polypeptide. We demonstrate here that oral administration of propentofylline, a stimulator of NGF synthesis in vitro, produced recovery of reduced NGF content. In aged rats (24-months-old), NGF content in the frontal cortex, parietal cortex, and hippocampus was lower than in young rats (8- weeks-old). Twenty-one-day successive administration of propentofylline (10 and 25 mg/kg, p.o.) produced recovery of reduced NGF content in the frontal cortex and parietal cortex of aged rats to a significant extent. There were no differences among aged, young, and propentofylline-treated groups in choline acetyltransferase activity in any brain regions. These results suggest that NGF content in the brain is reduced in aged rats and that oral administration of propentofylline leads to a recovery of this reduction.

Original languageEnglish
Pages (from-to)89-95
Number of pages7
JournalJapanese Journal of Psychopharmacology
Volume13
Issue number3
Publication statusPublished - 01-01-1993
Externally publishedYes

Fingerprint

Nerve Growth Factor
Oral Administration
Alzheimer Disease
Learning
Brain
Parietal Lobe
Frontal Lobe
Choline O-Acetyltransferase
propentofylline
Blood-Brain Barrier
Hippocampus
Clinical Trials
Peptides

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{4a064efe20214e758515a41b65f08e31,
title = "Impairment of learning and memory and the accessory symptom in aged rat as senile dementia model (3): Oral administration of propentofylline produces recovery of reduced NGF content in the brain of aged rats",
abstract = "The relationship between nerve growth factor (NGF) and senile dementia of the Alzheimer type is of interest. The administration of NGF in clinical trials has been expected; however, NGF cannot cross the blood brain barrier, since it is a polypeptide. We demonstrate here that oral administration of propentofylline, a stimulator of NGF synthesis in vitro, produced recovery of reduced NGF content. In aged rats (24-months-old), NGF content in the frontal cortex, parietal cortex, and hippocampus was lower than in young rats (8- weeks-old). Twenty-one-day successive administration of propentofylline (10 and 25 mg/kg, p.o.) produced recovery of reduced NGF content in the frontal cortex and parietal cortex of aged rats to a significant extent. There were no differences among aged, young, and propentofylline-treated groups in choline acetyltransferase activity in any brain regions. These results suggest that NGF content in the brain is reduced in aged rats and that oral administration of propentofylline leads to a recovery of this reduction.",
author = "Toshitaka Nabeshima and A. Nitta and T. Hasegawa",
year = "1993",
month = "1",
day = "1",
language = "English",
volume = "13",
pages = "89--95",
journal = "Neuropsychopharmacology Reports",
issn = "1340-2544",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Impairment of learning and memory and the accessory symptom in aged rat as senile dementia model (3)

T2 - Oral administration of propentofylline produces recovery of reduced NGF content in the brain of aged rats

AU - Nabeshima, Toshitaka

AU - Nitta, A.

AU - Hasegawa, T.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - The relationship between nerve growth factor (NGF) and senile dementia of the Alzheimer type is of interest. The administration of NGF in clinical trials has been expected; however, NGF cannot cross the blood brain barrier, since it is a polypeptide. We demonstrate here that oral administration of propentofylline, a stimulator of NGF synthesis in vitro, produced recovery of reduced NGF content. In aged rats (24-months-old), NGF content in the frontal cortex, parietal cortex, and hippocampus was lower than in young rats (8- weeks-old). Twenty-one-day successive administration of propentofylline (10 and 25 mg/kg, p.o.) produced recovery of reduced NGF content in the frontal cortex and parietal cortex of aged rats to a significant extent. There were no differences among aged, young, and propentofylline-treated groups in choline acetyltransferase activity in any brain regions. These results suggest that NGF content in the brain is reduced in aged rats and that oral administration of propentofylline leads to a recovery of this reduction.

AB - The relationship between nerve growth factor (NGF) and senile dementia of the Alzheimer type is of interest. The administration of NGF in clinical trials has been expected; however, NGF cannot cross the blood brain barrier, since it is a polypeptide. We demonstrate here that oral administration of propentofylline, a stimulator of NGF synthesis in vitro, produced recovery of reduced NGF content. In aged rats (24-months-old), NGF content in the frontal cortex, parietal cortex, and hippocampus was lower than in young rats (8- weeks-old). Twenty-one-day successive administration of propentofylline (10 and 25 mg/kg, p.o.) produced recovery of reduced NGF content in the frontal cortex and parietal cortex of aged rats to a significant extent. There were no differences among aged, young, and propentofylline-treated groups in choline acetyltransferase activity in any brain regions. These results suggest that NGF content in the brain is reduced in aged rats and that oral administration of propentofylline leads to a recovery of this reduction.

UR - http://www.scopus.com/inward/record.url?scp=0027483007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027483007&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 89

EP - 95

JO - Neuropsychopharmacology Reports

JF - Neuropsychopharmacology Reports

SN - 1340-2544

IS - 3

ER -